Develops innovative oral biotherapeutics designed to treat chronic gastrointestinal diseases.
Biora Therapeutics, Inc., previously known as Progenity, Inc., is a pioneering biotechnology firm based in San Diego, California. Specializing in the development of advanced oral biotherapeutics, the company is dedicated to revolutionizing treatment options for gastrointestinal (GI) diseases.
Biora Therapeutics' innovative therapeutics programs include a targeted therapeutics initiative featuring an ingestible smart capsule. This capsule is designed for precise delivery of therapeutics within the GI tract, specifically enhancing treatments for inflammatory bowel diseases. Additionally, the company's systemic therapeutics program utilizes another ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa, optimizing systemic uptake for enhanced therapeutic efficacy.
Complementing its therapeutic advancements, Biora Therapeutics is actively developing diagnostic devices aimed at characterizing the GI tract and diagnosing related diseases such as small intestine bacterial overgrowth. Through the integration of cutting-edge technologies, the company is committed to advancing diagnostic capabilities at the disease site, thereby improving patient outcomes through early and accurate diagnosis. With a foundation built on innnovation and scientific rigor, Biora Therapeutics continues to lead the charge in transforming GI healthcare through its pioneering biotherapeutic and diagnostic solutions.